Agilent Technologies Inc. (NYSE:A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum.

Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode microplate readers. Cytation 9 is designed to support advanced live‑cell and endpoint assays by combining automated microscopy with conventional microplate reading in a single system, supporting a range of cell‑based research applications.

In addition, Agilent will provide an early preview of the upcoming AI‑enabled software enhancement for the xCELLigence RTCA eSight, designed to bring the same straightforward, objective data analysis long valued in impedance measurements to label‑free live‑cell imaging, while supporting more consistent, reproducible results.

AACR attendees are invited to join Agilent at the Exhibitor Spotlight Theater for a session titled "Direct Targeted Methylation Sequencing (dTMS) with SureSelect: Targeted Long‑Read Sequencing for Native Variant and Methylation Profiling in Oncology." The session will be presented by Andrew Jenkins, biotechnology research associate at Wasatch Biolabs, and will examine the use of targeted long‑read sequencing approaches in oncology research.

Agilent will also highlight its collaboration with Oxford Nanopore Technologies, demonstrating the compatibility of Agilent SureSelect target enrichment chemistry with ONT's long-read sequencing platforms. By integrating SureSelect libraries into ONT sequencing workflows, researchers can pair hybrid-capture target enrichment with real-time, long-read sequencing to support applications such as target genomics, structural variant analysis, and methylation profiling.

Immediately preceding AACR 2026, Agilent's xCELLigence User Group Meeting will bring together the real-time cell analysis community to share best practices, applications, and real-world insights from functional cell-based research.

Agilent is continuing its collaboration with the AACR Foundation following a virtual 5K fundraiser held in October 2025 that raised $15,000 and funded 14 Scholars-in-Training awards. Agilent representatives will meet scholars supported through this initiative at the AACR Scholar‑in‑Training Award Reception and will promote the 5k fundraiser at the Agilent booth as part of its ongoing commitment to supporting early-career cancer researchers.

"At Agilent, our mission is to support advances in cancer research by providing integrated technologies and collaborative solutions," said Rita Shaknovich, chief medical officer at Agilent Technologies. "By delivering trusted answers, we aim to help researchers and clinicians make more informed decisions across the cancer research and care continuum."

Agilent will exhibit at booth No. 4527 and host additional scientific and networking events throughout the meeting.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260415203177/en/

MEDIA CONTACT:

Kate Coyle

Agilent Technologies Inc.

+1 302-633-7490

kate.coyle@agilent.com

Agilent Showcases Cancer Research Solutions at AACR 2026